---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-21-000113"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2021-09-20T23:59:59+00:00"
generated_at: "2026-06-29T02:36:05.538317+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Selecta Biosciences appoints Kevin Tan as CFO effective Sept 20, 2021

## Summary
- Kevin Tan named CFO; succeeds Ann K. Donohue who steps down as interim CFO but remains VP Finance.
- New CFO will receive $410K base salary, 40% target bonus, $75K signing bonus.
- Granted option to purchase 750K shares vesting over 4 years (25% at 12 months, remainder monthly).
- Tan previously served as Treasurer at Sarepta Therapeutics from July 2020 to September 2021.
- Severance includes 12 months salary, pro-rata bonus, and accelerated equity vesting upon qualifying termination.

## SEC filing metadata
- accession: 0001453687-21-000113
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2021-09-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368721000113/0001453687-21-000113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368721000113/selb-20210920.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-21-000113
- JSON: https://secwatch.observer/filing/0001453687-21-000113.json
- Plain text: https://secwatch.observer/filing/0001453687-21-000113.txt

## Key facts
- Executive change
  Kevin Tan was appointed as Chief Financial Officer at Cartesian Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On September 20, 2021, Selecta Biosciences, Inc. (the “Company”) announced that the Board of Directors (the “Board”) of the Company has appointed Kevin Tan as the Company’s Chief Financial Officer, effective upon the commencement of Mr. Tan’s full-time employment with the Company on September 20, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368721000113/0001453687-21-000113-index.htm
- Executive change
  Ann K. Donohue resigned as interim principal financial officer and principal accounting officer at Cartesian Therapeutics, Inc..
  - Action: resigned
  - Role: interim principal financial officer and principal accounting officer
  source text: Ann K. Donohue resigned from her duties as the Company’s interim principal financial officer and principal accounting officer, effective as of the Effective Date, and will continue to serve as the Company’s Vice President, Finance moving forward.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368721000113/0001453687-21-000113-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.